122 related articles for article (PubMed ID: 37847126)
21. Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3.
Ventero MP; Fuentes-Baile M; Quereda C; Perez-Valeciano E; Alenda C; Garcia-Morales P; Esposito D; Dorado P; Manuel Barbera V; Saceda M
PLoS One; 2019; 14(2):e0212581. PubMed ID: 30811476
[TBL] [Abstract][Full Text] [Related]
22. Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme.
Zhou H; Miki R; Eeva M; Fike FM; Seligson D; Yang L; Yoshimura A; Teitell MA; Jamieson CA; Cacalano NA
Clin Cancer Res; 2007 Apr; 13(8):2344-53. PubMed ID: 17438093
[TBL] [Abstract][Full Text] [Related]
23. p53 affects epigenetic signature on SOCS1 promoter in response to TLR4 inhibition.
Sheikh T; Sen E
Cytokine; 2021 Apr; 140():155418. PubMed ID: 33476981
[TBL] [Abstract][Full Text] [Related]
24. A suppressor of cytokine signaling 1 antagonist enhances antigen-presenting capacity and tumor cell antigen-specific cytotoxic T lymphocyte responses by human monocyte-derived dendritic cells.
Wang Y; Wang S; Ding Y; Ye Y; Xu Y; He H; Li Q; Mi Y; Guo C; Lin Z; Liu T; Zhang Y; Chen Y; Yan J
Clin Vaccine Immunol; 2013 Sep; 20(9):1449-56. PubMed ID: 23885028
[TBL] [Abstract][Full Text] [Related]
25. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells.
Zitzmann K; Brand S; De Toni EN; Baehs S; Göke B; Meinecke J; Spöttl G; Meyer HH; Auernhammer CJ
Cancer Res; 2007 May; 67(10):5025-32. PubMed ID: 17510435
[TBL] [Abstract][Full Text] [Related]
26. RNA interference-mediated silencing of SOCS-1 via lentiviral vector promotes apoptosis of alveolar epithelial cells in vitro.
Qian YR; Zhang QR; Cheng T; Wan HY; Zhou M
Mol Med Rep; 2012 Feb; 5(2):452-6. PubMed ID: 22086204
[TBL] [Abstract][Full Text] [Related]
27. Suppressors of cytokine signaling inhibit effector T cell responses during Mycobacterium tuberculosis infection.
Srivastava V; Vashishta M; Gupta S; Singla R; Singla N; Behera D; Natarajan K
Immunol Cell Biol; 2011 Oct; 89(7):786-91. PubMed ID: 21537342
[TBL] [Abstract][Full Text] [Related]
28. IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins.
Zimmerer JM; Lesinski GB; Kondadasula SV; Karpa VI; Lehman A; Raychaudhury A; Becknell B; Carson WE
J Immunol; 2007 Apr; 178(8):4832-45. PubMed ID: 17404264
[TBL] [Abstract][Full Text] [Related]
29. Identification and validation of SOCS1/2/3/4 as potential prognostic biomarkers and correlate with immune infiltration in glioblastoma.
Dai L; Han Y; Yang Z; Zeng Y; Liang W; Shi Z; Tao Y; Liang X; Liu W; Zhou S; Xing Z; Hu W; Wang X
J Cell Mol Med; 2023 Aug; 27(15):2194-2214. PubMed ID: 37315184
[TBL] [Abstract][Full Text] [Related]
30. Effect of SOCS1 silencing on proliferation and apoptosis of melanoma cells: An in vivo and in vitro study.
Yu SJ; Long ZW
Tumour Biol; 2017 May; 39(5):1010428317694315. PubMed ID: 28466787
[TBL] [Abstract][Full Text] [Related]
31. Bortezomib Sustains T Cell Function by Inducing miR-155-Mediated Downregulation of SOCS1 and SHIP1.
Renrick AN; Thounaojam MC; de Aquino MTP; Chaudhuri E; Pandhare J; Dash C; Shanker A
Front Immunol; 2021; 12():607044. PubMed ID: 33717088
[TBL] [Abstract][Full Text] [Related]
32. The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1.
Mathieu MG; Miles AK; Ahmad M; Buczek ME; Pockley AG; Rees RC; Regad T
Cell Death Dis; 2014 Feb; 5(2):e1061. PubMed ID: 24525737
[TBL] [Abstract][Full Text] [Related]
33. SOCS1 Gene Therapy for Head and Neck Cancers: An Experimental Study.
Kajiyama T; Serada S; Fujimoto M; Ohkawara T; Komori M; Hyodo M; Naka T
Anticancer Res; 2022 Jul; 42(7):3361-3372. PubMed ID: 35790291
[TBL] [Abstract][Full Text] [Related]
34. Anti-glioma effect of ginseng-derived exosomes-like nanoparticles by active blood-brain-barrier penetration and tumor microenvironment modulation.
Kim J; Zhu Y; Chen S; Wang D; Zhang S; Xia J; Li S; Qiu Q; Lee H; Wang J
J Nanobiotechnology; 2023 Aug; 21(1):253. PubMed ID: 37542285
[TBL] [Abstract][Full Text] [Related]
35. Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma.
Gui Y; Yeganeh M; Donates YC; Tobelaim WS; Chababi W; Mayhue M; Yoshimura A; Ramanathan S; Saucier C; Ilangumaran S
Oncogene; 2015 Nov; 34(46):5718-28. PubMed ID: 25728680
[TBL] [Abstract][Full Text] [Related]
36. Stimuli-Responsive Multifunctional Nanomedicine for Enhanced Glioblastoma Chemotherapy Augments Multistage Blood-to-Brain Trafficking and Tumor Targeting.
Martins C; Araújo M; Malfanti A; Pacheco C; Smith SJ; Ucakar B; Rahman R; Aylott JW; Préat V; Sarmento B
Small; 2023 Jun; 19(22):e2300029. PubMed ID: 36852650
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of miR-572 transcriptionally suppresses SOCS1 and p21 and contributes to human ovarian cancer progression.
Zhang X; Liu J; Zang D; Wu S; Liu A; Zhu J; Wu G; Li J; Jiang L
Oncotarget; 2015 Jun; 6(17):15180-93. PubMed ID: 25893382
[TBL] [Abstract][Full Text] [Related]
38. Role of SOCS1 in tumor progression and therapeutic application.
Zhang J; Li H; Yu JP; Wang SE; Ren XB
Int J Cancer; 2012 May; 130(9):1971-80. PubMed ID: 22025331
[TBL] [Abstract][Full Text] [Related]
39. Brain-targeted antigen-generating nanoparticles improve glioblastoma prognosis.
Wang W; Zhang M; Zhang Q; Mohammadniaei M; Shen J; Sun Y
J Control Release; 2022 Dec; 352():399-410. PubMed ID: 36309097
[TBL] [Abstract][Full Text] [Related]
40. Efficacy-shaping nanomedicine by loading Calcium Peroxide into Tumor Microenvironment-responsive Nanoparticles for the Antitumor Therapy of Prostate Cancer.
Wu D; Zhu ZQ; Tang HX; Shi ZE; Kang J; Liu Q; Qi J
Theranostics; 2020; 10(21):9808-9829. PubMed ID: 32863961
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
